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INTRODUCTION
Ovostatin is a 780,000 MW protein, originally isolated
from chicken egg white, which is active as a protease
inhibitor (1). Structural studies indicate that the protein
is a tetramer of identical subunits of 165,000 MW which can be
separated upon reduction with _-mercaptoethanol. Chicken
ovostatin is an inhibitor of metalloproteases such as
collagenase and thermolysin, and of acid proteases such as
pepsin and rennin (2). Ovostatin isolated from duck eggs (3)
and from crocodile eggs (4) appears to be similar to chicken
egg ovostatin, but with significant differences in structure
and function. Duck ovostatin contains a reactive thiol ester
which is not found in the chicken protein, and duck and
crocodile ovostatin inhibit serine proteases such as trypsin
and chymotrypsin, while chicken ovostatin does not. Electron
microscopy (4,5) of ovostatin indicates that two subunits
associate near the middle of each polypeptide to form a dimer
with four arms. Two of these dimers then associate to produce
a tetramer with eight arms, with the protease binding site
near the center of the molecule. Upon binding of the
protease, a conformational change causes all eight arms to
curl toward the center of the molecule, effectively trapping
the protease and sterically hindering access of the substrates
to its active site. The structural organization and mechanism
of action proposed for ovostatin are nearly identical to that
proposed for u2-macroglobulin, a serum protease inhibitor (6)
which may play an important role in regulation of proteases in
animal tissues.
Although the general arrangement of subunits appears to
be the same for all ovostatins studied, some differences have
been observed, with chicken ovostatin more closely resembling
reptilian ovostatin than the duck protein. This is a
surprising result, given the evolutionary relatedness of
chickens and ducks. It is possible that the difference in
structures may be due to deformed subunit arrangements which
occur during the processing and fixing necessary for electron
microscopy (4). Examination of the native structure of these
proteins using X-ray crystallography would help clarify these
discrepancies.
BODY
Obviously, it is necessary to have good quality crystals
of ovostatin if x-ray crystallography is to be performed. Such
crystals could also be used as a model system to study and
understand numerous aspects of crystal growth for such a large
protein. For these reasons, attempts have been made at MSFC
to prepare crystals of chicken egg white ovostatin. Ovostatin
has been purified using slight modifications of published
procedures. SDS-gel electrophoresis under reducing conditions
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indicated a large band of MW 165,000 and a smaller band at MW
88,000. This smaller band has been reported to be a fragment
produced by action of the bound protease on the ovostatin (7)
and has also been found to occur due to autolytic degradation
of duck ovostatin. Such autolytic degradation had not
previously been observed for chicken ovostatin (7). Attempts
to crystallize the ovostatin preparations have had limited
success, with reasonable size crystals only occurring on a few
occasions. For this reason, it was deemed necessary to
investigate the protease inhibitory activity of the ovostatin
preparations to determine if native, active molecules were in
fact being purified.
One assay for ovostatin employs the metalloprotease
thermolysin and uses azocasein as its substrate in a reaction
carried out at 23°C. Nagase et al. (1) have reported that
using this assay, they have observed a 1:1 stoichiometric
relationship between thermolysin and ovostatin. Thus, when
there is a molar ratio of ovostatin:thermolysin of 0.5 one
should observe 50% inhibition of the protease. Initial trials
using this assay at MSFC resulted in absorbance differences
between the blanks and the positive controls of only 0.3 - 0.6
absorbance units. Also, the azocasein substrate gave higher
readings with increasing storage time at 4"C. Hemoglobin was
tried as an alternate substrate for the thermolysin, but was
not a good substrate for the enzyme. After several
preparations of new azocasein solutions it was found that
storing the azocasein solution at -20°C gave more stable, low
blank values for the assay. Increasing the assay temperature
from 23°C to 37"C increased the activity of the thermolysin
and hence, the absorbance readings, as expected. However, it
was observed that ovostatin inhibition of thermolysin was
decreased at molar ratios of ovostatin:thermolysin less than
1.0. The observed temperature dependence of the assay is
shown in Figure i. Since ovostatin is expected to be a
physiologically important inhibitor of bacterial proteases in
the egg at the normal chicken body temperature of 42 ° C these
results are curious and warrant further investigation.
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Several ovostatin preparations were assayed and found to
yield less than a 50% inhibition of the thermolysin when used
at a 0.5 molar ratio of ovostatin:thermolysin. These
preparations were analyzed by SDS-polyacrylamide
electrophoresis, and all but one appeared to be quite pure,
except that the 88KMW degradation product was visible in
nearly all the lyophilized, stored preparations. Assay and
gel electrophoresis were then performed on freshly prepared
ovostatin at several key steps during the purification
procedure. The preparation did not have much of the 88K band
present and seemed to be nominally active through the ion
exchange column portion of the isolation procedure. At this
point it was also observed that the ovostatin solutions stored
at 4°C appeared to lose activity with time. Thus,
preparations of ovostatin that required more than 5-6 days to
complete could be becoming less active during the isolation.
Many of the blood coagulation factors are proteases and
it was of interest to determine whether ovostatin might
inhibit one or more of these. Thrombin, which acts near the
end of the blood clotting cascade, is readily available
commercially, so ovostatin was examined for its ability to
inhibit the action of thrombin on fibrinogen and the
subsequent formation of a fibrin clot. Assays at 37°C with up
to a 2 fold molar excess of ovostatin over thrombin did not
indicate any inhibition. Native polyacrylamide gels of
ovostatin incubated wi_h thermolysin or with thrombin
indicated that the thermolysin bound to ovostatin and changed
its electrophoretic mobility, but the thrombin did
not.
Assays of ovostatin performed at both high (i.0 mg/ml)
and low (0.025 mg/ml) concentrations gave conflicting and
irreproducible results. It was thought that perhaps there was
either an as yet unreported requirement for some cation for
ovostatin activity, or that some cation could inactivate the
ovostatin. To test this hypothesis, ovostatin was incubated
with 1 mM EDTA prior to incubating it with thermolysin. The
results of this experiment indicated that this treatment may
have produced a slight increase in the activity of the
ovostatin when assayed at a molar ratio of 0.5. However,
incubation of ovostatin with 5 mM EDTA resulted in the
opposite effect, decreasing the ovostatin activity at a 0.5
molar ratio.
Several attempts were made to crystallize different
ovostatin preparations that had been stored lyophilized at -
20°C, but none were successful.
CONCLUSIONS
As is often the case in science, these results have
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raised more questions than they have answered. While it
appears that ovostatin prepared at MSFC has some inhibitory
activity towards thermolysin, it may not have optimal
activity. This may or may not be the reason for the
difficulty in crystallizing these preparations. Although the
crystallization problem was not solved, several important
observations were made:
1) Azocasein solutions must be stored at -20 ° C.
2) Thermolysin solutions should be made up as concentrated
solutions in 50% glycerol, stored at -20 ° C and diluted
to the appropriate concentration immediately before use.
3) Hemoglobin is not a good substrate for this assay.
4) Chicken ovostatin does not inhibit thrombin.
5) The inhibition of thermolysin by ovostatin is temperature
dependent at low ovostatin:thermolysin ratios, and
decreases as one approaches physiological temperatures.
6) It appears that there are as yet undefined variables in
the purification of active chicken ovostatin.
More work needs to be done to identify the reason for the
appearance of the 88KMW band in the ovostatin preparations
and to discern the appropriate conditions to produce ovostatin
crystals.
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